Science Policy 2025–2029: From expertise to impact
The MEB has a new Science Policy for 2025-2029. Four key themes will guide regulatory science at the MEB for the coming four years. The new Science Policy was launched yesterday, at TivoliVredenburg in Utrecht, during the MEB Science Day 2025.
From expertise to impact: Science as the foundation for regulatory innovation, as the new policy is titled, builds on the 2020–2024 Science Policy. It responds to a rapidly evolving world, shaped by fast-paced technological and societal developments.
As a regulatory authority, it is vital that we continue to learn, innovate and reflect. Regulatory science plays a key role in this. It enables us to contribute through scientific research both to the quality of our assessments and to the ongoing development of the broader system for medicines evaluation and surveillance.
In the light of these ongoing developments, the MEB has identified a number of priority areas of expertise in its Strategic Business Plan 2024–2028. These priorities are reflected in our updated science policy, which focuses on four main themes:
- Replacement, reduction and refinement of animal studies (3Rs)
- Data-driven assessment
- Personalised medicine
- New pharmaceutical legislation
You can find more details on each of these themes in the policy document. In addition, an in-depth interview with Marjon Pasmooij (Head of the Science Office), Eric Boersma (MEB Board Member and Chair of the MEB’s Science Committee), and Aimad Torqui (Division Head for Europe, Medicines Use and Veterinary Affairs) highlights the vital role of scientific research in supporting the processes of medicines assessment and surveillance.
